Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

One of the largest benefit managers, CVS Health’s Caremark, made the decision to exclude Zepbound in spite of research that found that it resulted in more weight loss than Wegovy, which will ...

Despite lower-than-expected first-quarter revenues and a guidance cut for 2025, NVO stock price rose post its earnings ...

Eli Lilly & Co has experienced a significant stock price drop of 10.58% over the past week, despite delivering impressive first-quarter results for 2025. The company’s revenue s ...